Kabir Life Sciences And Research Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-12-2024
- Paid Up Capital ₹ 0.10 M
as on 11-12-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 680.89%
(FY 2016)
- Profit 96.25%
(FY 2016)
- Ebitda 91.47%
(FY 2016)
- Net Worth -2.08%
(FY 2016)
- Total Assets 149.67%
(FY 2016)
About Kabir Life Sciences And Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Tajender Kaur, Mandeep Sidana, and Rupinder Kaur serve as directors at the Company.
- CIN/LLPIN
U24232CH2014PTC034997
- Company No.
034997
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Feb 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Kabir Life Sciences And Research Private Limited offer?
Kabir Life Sciences And Research Private Limited offers a wide range of products and services, including Sexual Wellness Products, Fertility Enhancer, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Nutraceuticals & Dietary Supplements, Nutritional Supplements, Cardiovascular Drugs & Medication, Cardiac Drugs, Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant.
Who are the key members and board of directors at Kabir Life Sciences And Research?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tajender Kaur  | Director | 28-Feb-2014 | Current |
| Mandeep Sidana | Director | 16-Apr-2019 | Current |
| Rupinder Kaur | Director | 28-Feb-2014 | Current |
Financial Performance of Kabir Life Sciences And Research.
Kabir Life Sciences And Research Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 680.89% increase. The company also saw a substantial improvement in profitability, with a 96.25% increase in profit. The company's net worth dipped by a decrease of 2.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kabir Life Sciences And Research?
In 2017, Kabir Life Sciences And Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kabir Life Sciences And Research?
Unlock and access historical data on people associated with Kabir Life Sciences And Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kabir Life Sciences And Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kabir Life Sciences And Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
